Pfizer (PFE) Q2 2021 Earnings


Results

  • EPS: $1.07 vs $0.97 expected, an earnings surprise of 10.3%, rising 72.6% YoY

  • Revenue: $18.98 billion vs $18.74 billion expected, rising 92.4% YoY

$7.8 billion from Covid-19 vaccines, with just under half of Pfizer’s total revenue coming from all vaccines

Oncology unit revenue increased19% YoY to $3.1 billion

Hospital unit increased 21% YoY to $2.2 billion in revenue

Internal medicine unit revenue increased 5% YoY to $2.4 billion

  • Pfizer's business excluding the COVID-19 vaccine has achieved 10% year-over-year operational revenue growth, indicating strength outside of that key area as well, surpassing Q1’s YoY non-Covid-19 vaccine growth of 6%

Guidance

  • EPS between $3.95-4.05, revised up from $3.55-3.65

  • Revenue between $78-80 billion, revised up from $70.5-72.5 billion

Vaccine revenue of $33.5 billion, revised up from $26 billion

Due to concerns of Delta variant and expected to gain full approval of it by the FDA by January 2022

Could file for emergency approval for the booster shot with the FDA as early as August this year


Market Reaction

  • Share price rose 3% to close of the market

10 views0 comments